Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT)
jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel).
Highlighting the uncertainty that hangs over the US economy, first-quarter GDP nowcasts from two regional Fed banks report sharply different estimates.
Investor sentiment was shocked by Trump's 25% tariff on auto imports, increasing inflation fears. But some ETFs performed well, with gains up to 22.8%.
Goldman Sachs analyst shares key takeaways from 2025 Shoptalk Conference, highlighting conversational and personalized eCommerce, critical video content, and the role of AI in improving brand experience.
Investors should prepare for a 2008-style crisis.Benzinga warns of potential economic crisis predicted by Peter Schiff in 2008. Tariffs, rising interest rates, misguided Fed policy may cause trouble.
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval.
